Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono

This page shows the latest Merck Serono news and features for those working in and with pharma, biotech and healthcare.

Lundbeck drops Parkinson’s drug acquired in €905m deal

Lundbeck drops Parkinson’s drug acquired in €905m deal

Lundbeck paid 100m upfront for Merck Serono spinout Pexton and foliglurax two years ago, with another 805m tied to  development and sales milestones.

Latest news

More from news
Approximately 21 fully matching, plus 136 partially matching documents found.

Latest Intelligence

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    When Merck acquired Serono, the company also acquired several manufacturing facilities in the canton of Vaud. ... The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline,

  • The search for treatments for Parkinson’s disease The search for treatments for Parkinson’s disease

    and a decade as senior director of neurodegenerative diseases research at Merck Serono where he served as its leader for in vitro pharmacology in neurology, including in multiple sclerosis, Parkinson’s

  • A rare opportunity A rare opportunity

    The disappearance of that opportunity combined with changes at Merck following its 10.6bn acquisition of Serono gave Neil the momentum to set up his own consultancy business in 2007. ... He worked for a number of pharma clients, including Eisai and Merck

  • Sustainable solutions Sustainable solutions

    Over the summer Alex was appointed chair of the EMG, taking over from Merck' Serono's David Garmon-Jones, and he says both the EMG and its wider, UK industry counterpart ... In May 2014 it paid $14.2bn for Merck &Co's consumer health unit.

  • Deal Watch October 2015 Deal Watch October 2015

    This month's deal between Merck Serono (Merck KGaA) and BioMarin is a good example of this approach. ... Acquisition - company. 580. Merck Serono/ BioMarin. Kuvan and pegvaliase (Kuvan marketed; pegvaliase p3).

More from intelligence
Approximately 1 fully matching, plus 21 partially matching documents found.

Latest appointments

More from appointments
Approximately 5 fully matching, plus 32 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Personalised medicine: driving a need for greater diversity in clinical trials
Kate Shaw, Innovative Trials' Founder & CEO, investigates one of the biggest challenges facing clinical research today....
Congresses and conferences
Superstar congresses and conferences will stay centre stage but now share the limelight with virtual and hybrid events
With the pandemic having dimmed the lights on pharma conferences, their virtual and hybrid replacements have grasped the opportunity and are here to stay...
Cervical Cancer Prevention Month
In this first 2022 blog, the Innovative Trials' Equality & Diversity committee will be looking at raising awareness around Cervical Cancer...